Biomea Fusion, Inc.
corporate_fare Company Profile
Biomea Fusion, Inc. (NASDAQ:BMEA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for BMEA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-13, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BMEA spans 424B5, 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Biomea's Oral GLP-1 BMF-650 Shows Up to 6.1% Weight Loss in Phase 1, Plans Partnership
- Biomea Fusion Scraps Planned Stock Offering, Raising Cash Concerns
- Biomea Fusion Launches Underwritten Offering of Common Stock and Pre-Funded Warrants
- Biomea Fusion Q2 Loss Narrows to $8.3M, Cash Runway Extended to Q2 2027
- Shareholders Elect Directors with Significant Dissent
Financial Snapshot
Short Interest & Short Volume
4.84 days to coverFINRA reported short interest of 15,713,730 shares in BMEA as of the October 15, 2026 settlement, a 11.6% increase from the prior period — about 4.8 days to cover at its recent average daily volume. On November 6, 2026, 16.5% of BMEA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BMEA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-22.
Underwritten Offering Launched · Underwriter Compensation Terms
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →